FDA approves Vismodegib for basal cell carcinoma

4 Comments so far

>> Wednesday, February 01, 2012

Vismodegib (see structure) under trade name Erivedge from Roche has been approved by FDA for the treatment of basal cell carcinoma (BCC), the most common type of skin cancer. The drug is intended for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma who are not candidates for surgery and radiation. The drug works by inhibiting the hedgehog pathway, a pathway active in most basal cell cancers. It is the first FDA-approved drug for BCC that inhibits the hedgehog pathway. 


  © Medchemblog, 2009-present Webnolia by Ourblogtemplates.com 2009

Back to TOP